OmniAb, Inc.
Erika Luib has worked in various roles throughout their career. Erika began their career at Captisol, a Ligand technology company, in 2006 as a Captisol employee. Erika then moved on to Ligand Pharmaceuticals in the same year and served as the Associate Director of Marketing. In this role, Erika was responsible for marketing activities related to Captisol, a patent-protected cyclodextrin with enhanced solubility and stability. Erika worked at Ligand Pharmaceuticals for a significant duration of time, from 2006 to 2022. Currently, Erika is employed at OmniAb, Inc. as the Director of Technology Marketing & Brands since November 2022.
Erika Luib obtained a Bachelor of Arts degree in Communications from UC San Diego. The start and end years of their education are not specified.
This person is not in any teams
This person is not in any offices
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.